

Ensysce Biosciences, Inc.
7946 Ivanhoe Avenue, Suite 201
La Jolla, California 92037

November 20, 2023

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549
Attention: Jason Drory, Esq.

Re: Ensysce Biosciences, Inc.
Registration Statement on Form S-1
SEC File No. 333-275456
Filed November 9, 2023
Pre-Effective Amendment No. 1 filed November 17, 2023

Ladies and Gentlemen:

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Ensysce Biosciences, Inc. (the "**Company**") hereby requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-275456) (the "**Registration Statement**") be accelerated so that the Company's Registration Statement will become effective at 4:00 PM, Eastern Time, on November 21, 2023, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Hamilton Sanders LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Troutman Pepper Hamilton Sanders LLP, by calling Eric D. Kline at (412) 454-5046 or Gregory Rubis at (609) 951-4105.

Please direct any questions or comments concerning this request to Eric Kline or Gregory Rubis.

ENSYSCE BIOSCIENCES, INC.

By: /s/ Lynn Kirkpatrick
Name: Dr. Lynn Kirkpatrick
Title: President and Chief Executive Officer

Cc: Eric D. Kline, Troutman Pepper Hamilton Sanders LLP
Gregory Rubis, Troutman Pepper Hamilton Sanders LLP
